17(R)-Resolvin D3
(Synonyms: Aspirin-triggered Resolvin D3, 17-epi-Resolvin D3, AT-RvD3, 17(R)-RvD3) 目录号 : GC45307
An aspirin-triggered epimer of resolvin D3
Cas No.:1427475-53-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
17(R)-Resolvin D3 (17(R)-RvD3) is an aspirin-triggered epimer of resolvin D3 .1 It is produced from docosahexaenoic acid by COX-2 in the presence of aspirin via a 17(R)-hydroperoxy DHA (17(R)-HDHA;) intermediate and has been found in mouse inflammatory exudates.1,2 17(R)-RvD3 reduces transmigration of isolated human polymorphonuclear cells (PMNs) and induces efferocytosis of apoptotic PMNs by macrophages.2 17(R)-RvD3 (10 ng/animal) reduces transmigration of neutrophils into the peritoneal cavity, as well as decreases the levels of IL-6 and increases the levels of IL-10 in inflammatory exudate in a mouse model of zymosan-induced peritonitis. It activates GPR32 in a β-arrestin reporter assay and increases phagocytosis to a greater degree in CHO cells overexpressing GPR32 compared to mock-transfected cells. 17(R)-RvD3 increases phagocytosis of etoposide-generated tumor cell debris by monocyte-derived macrophages in H460 human lung carcinoma cells in a concentration-dependent manner.3 It also inhibits tumor growth in a mouse model of Lewis lung carcinoma when administered at a dose of 0.6 μg/kg per day.
References
1. Winkler, J.W., Uddin, J., Serhan, C.N., et al. Stereocontrolled total synthesis of the potent anti-inflammatory and pro-resolving lipid mediator resolvin D3 and its aspirin-triggered 17R-epimer. Org. Lett. 15(7), 1424-1427 (2013).
2. Dalli, J., Winkler, J.W., Colas, R.A., et al. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem. Biol. 20(2), 188-201 (2013).
3. Gilligan, M.M., Gartng, A., Sulcier, M.L., et al. Aspirin-triggered proresolving mediators stimulate resolution in cancer. Proc. Nat. Acad. Sci. USA 116(13), 6292-6297 (2019).
| Cas No. | 1427475-53-3 | SDF | |
| 别名 | Aspirin-triggered Resolvin D3, 17-epi-Resolvin D3, AT-RvD3, 17(R)-RvD3 | ||
| Canonical SMILES | O[C@H](C/C=C\CC)/C=C/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@@H](O)CCC(O)=O | ||
| 分子式 | C22H32O5 | 分子量 | 376.5 |
| 溶解度 | DMF: 50 mg/ml,DMSO: unstable,Ethanol: 50 mg/ml,PBS (pH 7.2): 0.5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.656 mL | 13.2802 mL | 26.5604 mL |
| 5 mM | 0.5312 mL | 2.656 mL | 5.3121 mL |
| 10 mM | 0.2656 mL | 1.328 mL | 2.656 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >90.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet